News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PCI Synthesis Wins Four 2013 CMO Leadership Awards



11/4/2013 12:38:08 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Newburyport, Mass., Nov. 4, 2013 – PCI Synthesis, Inc. (www.pcisynthesis.com), a Boston-based Contract Manufacturing Organization (CMO) that manufactures new chemical entities (NCE), generic active pharmaceutical ingredients (API’s), and complex pharmaceutical intermediates, announced that it won four categories in the 2013 Life Science Leader CMO Leadership Awards. The four categories are Quality, Innovation, Productivity, and Reliability.

The CMO Leadership Awards are designed to provide credible information to help pharmaceutical and biopharmaceutical executives vet potential partners for pharmaceutical contract manufacturing. The annual awards are based on survey responses from more than 10,000 pharmaceutical and biopharmaceutical executives conducted by Nice Insight and sponsored by Life Science Leader magazine. The award recognizes those contract manufacturing organizations that are the most highly rated by industry respondents. The survey covered more than 100 CMOs.

According to Rob Wright, Chief Editor at Life Science Leader, "Being a winner in one category is quite an accomplishment; winning in multiple categories is truly outstanding. This year, only eight companies out of more than 100 CMOs were recognized as being in the top 20 percent in four different categories."

“The awards are based on perceptions of our customers and other peers in the industry – and winning awards across four categories is a tribute to our skilled employees, terrific clients and the recent expansions and investment in our organization and facilities,” said Edward S. Price, President of PCI Synthesis.

PCI, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as active pharmaceutical ingredients (APIs), currently has four new chemical entities in clinical development that were recently included in the "Top 50 Drugs in Development to Watch" list. In addition, over the past two years, PCI has launched more than five new proprietary APIs for the generic market with exclusive supply agreements – bringing its total to 17 exclusive APIs in its overall pipeline.

The company’s growth over the past several years was recognized last month in the annual list of "The largest life science companies in Massachusetts" published by the Boston Business Journal. This list is based on both the number of Massachusetts employees and revenue.

“The biotech/pharma development market in Massachusetts continues to be robust, and growing. We’ve positioned the company to be at the forefront of the state’s ever expanding biotech cluster,” added Price, who also serves as co-chair of MassBio’s Massachusetts CRO/CMO Committee.

About PCI Synthesis

PCI Synthesis is a 15-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides small and mid-sized companies with expertise needed to manufacture complex small molecules to be used in both the branded and generic market. To learn more about PCI Synthesis, its proprietary APIs, and R&D, please visit www.pcisynthesis.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES